Challenges in accessing NHS prescribed Wegovy highlight gaps in the UK’s weight management services
In the UK, the rollout of the weight-loss drug Wegovy by the National Health Service (NHS) has been significantly less widespread than anticipated. Since its introduction, Wegovy has been prescribed approximately 3,300 times, a figure starkly lower than the 13,500 prescriptions projected by the National Institute of Health and Care Excellence (Nice) for the drug’s first year. This shortfall is attributed to a combination of factors, including an international shortage of the drug and a domestic scarcity of specialised weight management clinics required for its distribution.
The Financial Times, analysing NHS England data, notes that this slow uptake occurs amidst escalating demand, especially after recent endorsements from the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA has expanded Wegovy’s use not only for weight reduction but also as a preventative treatment against severe heart conditions and strokes in adults with overweight and obesity.
Compounding the issue, the NHS faces a shortage of the drug due to global supply constraints, which has led to a prioritisation of Ozempic—another drug by the same manufacturer, Novo Nordisk, intended for type-2 diabetes but containing the same active ingredient, semaglutide. This decision reflects the broader challenges in managing pharmaceutical supplies amidst varying clinical demands.
The limited availability of “tier 3” specialist weight management services, which provide comprehensive support including counselling, physiotherapy, and dietary advice, further hinders access. These services are crucial as they replicate the conditions of the clinical trials conducted by Novo Nordisk, yet there are barely over 20 such clinics across the UK, some with extensive waiting lists.
Nerys Astbury, a professor at Oxford University specialising in diet and obesity, highlighted the inconsistency in the availability of these services. “The provision of tier 3 weight management services is very patchy across the country. Some areas are well-serviced, whilst others lack these services entirely, or face significant delays,” she explained. This disparity has led some individuals to pursue private treatment, which is not a viable option for everyone due to the high costs—up to £299 for a month’s supply at commercial pharmacies like Boots.
Despite these obstacles, NHS prescriptions of Wegovy have been on a gradual rise, reaching about 770 by April from its UK approval in September of the previous year. Looking forward, projections indicate that by 2027, nearly 4 million Britons could qualify for semaglutide treatment under NHS guidelines, with expectations that almost 50,000 will receive it annually.
However, the Department of Health and Social Care has warned that drugs in the GLP-1 category, which includes Wegovy, may continue to face shortages until at least the end of 2024. In response, Novo Nordisk has prioritised maintaining a stable supply of Ozempic for diabetes patients over Wegovy, reflecting a strategic decision to meet critical healthcare needs first.
Despite these prioritisation efforts, the future of weight management drugs like Wegovy and the newly mentioned Mounjaro from Eli Lilly, which might soon be prescribed without the need for tier 3 services, points towards a potential shift in how obesity treatments are administered in the UK. Professor Astbury remains cautiously optimistic about these developments, yet she underscores the necessity for readiness in service provision: “It’s promising that access might improve, but we must ensure that the healthcare settings are prepared to support patients effectively.”
In summary, while Wegovy offers significant potential in combating obesity and related health issues, its effective deployment within the NHS is hampered by systemic issues in drug supply and specialised service availability. These challenges highlight the need for strategic improvements in healthcare logistics and infrastructure to better serve the population’s needs.
Read MoreBritain’s drug regulator approves Novo Nordisk’s weight loss drug Wegovy to cut heart disease risk in patients with obesity
On Tuesday, the 23rd of July, 2024, the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) granted approval for an additional use of Novo Nordisk drug, semaglutide (marketed as Wegovy), targeting the reduction of cardiovascular risks in adults with overweight and obesity.
Originally sanctioned for obesity treatment and weight management in conjunction with dietary, physical, and behavioural interventions, semaglutide, a GLP-1 receptor agonist, has now emerged as the pioneering prescription weight loss medication to thwart cardiovascular incidents. This includes the prevention of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in individuals possessing a Body Mass Index (BMI) of at least 27 kg/m2 who already suffer from established cardiovascular disorders.
The endorsement by MHRA is supported by recent data derived from a post-approval clinical trial, indicating that a weekly subcutaneous injection of semaglutide (2.4 mg) over a span of up to five years considerably diminishes the occurrence of major adverse cardiovascular events (MACE) when compared to a placebo.
In a significant international study, which randomly allocated more than 17,600 participants to either receive Wegovy or a placebo, the treatment with Wegovy was observed to reduce the risk of major adverse cardiovascular events by 20%. These events transpired in only 6.5% of the Wegovy group, as opposed to 8% among those who received the placebo.
Recent research underscores the efficacy of semaglutide in augmenting the life quality of individuals with cardiovascular diseases by substantially lowering the risk of severe cardiac episodes.
Furthermore, in a strategic expansion move, Novo Nordisk procured a 200-acre plot earlier this month in Odense, Denmark’s third-largest city. The company has initiated preliminary excavation activities at this site, potentially setting the stage for a new manufacturing facility.
The surge in demand has propelled the pharmaceutical giant to invest billions in amplifying its production capacities in both Denmark and the United States. While the specific purpose of the new site in Odense remains to be officially confirmed, a report by Reuters in January highlighted that the site might accommodate facilities crucial for the fill-finish process involved in injection pen manufacturing.
A company statement released to Reuters mentioned, “With the political processes and approvals in place, we are pleased to announce that Novo Nordisk is now the owner of the site in Tietgenbyen in Odense.”
The company further indicated that the decision-making process regarding the precise use of the new site would conclude by the end of the year, post-internal approvals. The environmental report sheds light on future plans, which include establishing a packaging facility by 2026 and a factory for moulding plastic components necessary for pen and possibly tablet production by 2030.
Read MoreRoche highlights promising results from early obesity drug trial
Swiss pharmaceutical giant Roche has announced encouraging outcomes from an early-stage trial for its new obesity drug candidate, CT-996. This development emerges from its acquisition of Carmot Therapeutics. On Wednesday, 17th of July, 2024, Roche revealed that CT-996, a once-daily oral medication, demonstrated a significant placebo-adjusted average weight loss of 6.1% over a span of four weeks among patients with obesity who do not have diabetes.
The positive trial results, reported during a Phase I study, have notably propelled Roche’s stock up by 6.1% to a one-year peak at 1025 GMT. This surge mirrors the market’s response to earlier favourable results from another Carmot drug, underlining Roche’s burgeoning presence in the competitive obesity treatment landscape.
Currently, Roche is positioning itself against established players like Novo Nordisk and Eli Lilly, whose injectable weight-loss therapies are witnessing soaring demand. Forecasts for the market of such obesity treatments are expected to potentially reach $150 billion by the early 2030s.
Roche’s CT-996, appealing particularly to those who prefer pills over injections, has been well-received with primarily mild or moderate gastrointestinal side effects, comparable to those associated with other drugs in the weight-loss category.
Despite the promising data, Roche is navigating a rapidly evolving and crowded sector, aiming to develop oral formulations that effectively match the efficacy of the more prevalent weekly injections. Other companies, including Structure Therapeutics and Pfizer, are also making significant headway in this space. Structure Therapeutics reported a 6.2% weight loss after 12 weeks in a Phase II trial, while Pfizer recently outlined plans for trials of its revamped daily pill. Additionally, Viking Therapeutics showed a 3.3% weight loss at the four-week mark with its pill.
Manu Chakravarthy, Head of Metabolic Drug Development at Roche, commented on the challenges and potentials within the industry, noting the inherent unpredictability of side effects with small-molecule chemical compounds compared to the established peptide-based obesity drugs. “Having worked with many small molecules for most of my life, I can say it’s never over until it’s over. It’s a very different beast from an injectable formulation,” Chakravarthy stated.
Looking forward, Roche plans to advance CT-996 into Phase II clinical trials next year. Meanwhile, another Carmot-derived drug, CT-388, which is a self-administered once-weekly injection similar to the leading products from Novo and Lilly, also showed success in its Phase I trial in May.
In a strategic move to strengthen its position in the market, Roche acquired Carmot Therapeutics in December for $2.7 billion, signalling its commitment to expanding its portfolio in the obesity drug arena and challenging the dominance of Novo and Lilly in this field.
Read MoreConcerns arise over rare eye condition linked to popular weight loss injections
Recent research indicates that individuals utilising semaglutide injections, commonly used for weight management and type 2 diabetes, have a quadrupled risk of developing a severe eye disorder compared to non-users. The medications in question, Ozempic and Wegovy, have been associated with an elevated risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare but potentially harmful eye condition.
Despite the concerning findings, the researchers involved have clarified that the overall incidence of the condition among users remains low, and definitive evidence that semaglutide is the direct cause of NAION is still lacking.
Produced by pharmaceutical giant Novo Nordisk, Wegovy is designed to promote significant weight loss. Clinical trials have shown that some individuals experience a reduction in body weight exceeding 10% after using the medication.
The popularity of these weight loss injections has surged recently, fueled in part by celebrity endorsements and public testimonials about their effectiveness in achieving rapid weight loss.
However, a rise in the unregulated online purchase of semaglutide injections has alarmed health professionals. The absence of proper checks on these internet-sourced medications raises serious concerns about their safety.
Further worries have been voiced over the misuse of semaglutide, with indications that the drug is increasingly being used for cosmetic weight loss, particularly to achieve a ‘beach-body’.
The common side effects associated with semaglutide include stomach pain, nausea, constipation, diarrhoea, and vomiting. Additionally, both Ozempic and Wegovy have been linked to potentially serious changes in vision, according to the latest studies.
NAION, which affects up to 10 in every 100,000 people, leads to vision loss due to diminished blood flow to the optic nerve and currently lacks an effective treatment.
Dr Joseph Rizzo, a leading researcher in the study, stated, “Our findings should be viewed as being significant but tentative, as future studies are needed to examine these questions in a much larger and more diverse population.”
A Novo Nordisk spokesperson responded to the findings by noting that NAION is not recognised as a known adverse drug reaction in the marketed formulations of semaglutide, which include Ozempic, Rybelsus, and Wegovy. They highlighted that semaglutide has been thoroughly examined in extensive real-world evidence studies and robust clinical development programmes.
Professor Graham McGeown from Queen’s University Belfast commented on the issue, emphasising the need for additional research given the sharp rise in semaglutide usage and its potential approval for uses beyond obesity and type 2 diabetes. “This issue deserves further study – but possible drug side-effects always need to be balanced against likely benefits,” he said.
Read MoreOzempic and other GLP-1 drugs show promise in reducing obesity-related cancer risks
In a significant medical discovery, a class of diabetes medications, including the widely-used drug Ozempic, has been linked to a decreased risk of numerous obesity-associated cancers. This revelation was detailed in a study published in the Journal of the American Medical Association (JAMA) on Friday, 5th of July, 2024.
The research meticulously analysed the health outcomes of Type 2 diabetes patients from 2005 to 2018, focusing on those treated with insulin compared to those administered GLP-1 agonists, such as Ozempic. The findings indicated a notable reduction in the risk of developing 10 out of 13 types of cancer examined in the study. The cancers showing decreased risk include those of the kidney, pancreas, oesophagus, ovaries, liver, and colorectum.
However, the study observed no substantial reduction in the risk of thyroid cancer and breast cancer among postmenopausal women. These findings underscore the complex relationship between metabolic disorders and cancer risks.
“Obesity is well known to be associated with at least 13 cancer types,” stated Rong Xu, the study’s lead author, in an email correspondence with AFP. Xu further commented, “Our study provides evidence that GLP-1RAs hold promise in breaking the link between obesity and cancer.”
The research not only highlights the efficacy of GLP-1 receptor agonists (GLP-1RAs) in managing diabetes but also their potential role in cancer prevention. The study encompassed several drugs within this category, including semaglutide, marketed as Ozempic, and liraglutide, among others, with Ozempic receiving approval in the United States in 2017.
GLP-1 agonists have been utilised for approximately two decades; however, a new generation of these drugs, including Ozempic, has gained popularity for their enhanced effects on weight loss.
The protective benefits observed might influence healthcare providers to favour GLP-1 treatments over other therapeutic options such as insulin for diabetes patients, as suggested by Xu. This shift could represent a pivotal evolution in the management of diabetes and its associated cancer risks, marking a significant stride forward in integrative disease prevention strategies.
Read MoreInnovative obesity drug pemvidutide maintains muscle mass in Altimmune trials
Altimmune, a biotechnology company, recently shared encouraging results from their Phase II MOMENTUM study concerning their investigational obesity treatment, pemvidutide. The study data, which was presented at the 84th Scientific Sessions of the American Diabetes Association, revealed that pemvidutide not only facilitates significant weight loss in adults diagnosed with obesity but also uniquely preserves lean muscle mass.
Participants in the study who were administered a 1.2-mg dose of pemvidutide experienced an average weight reduction of 10.3% over a period of 48 weeks. This average increased to 11.2% for those on the 1.8-mg dosage and reached 15.6% for subjects receiving the 2.4-mg dose. In stark contrast, the placebo group saw a minimal weight loss of just 2.2% under the same conditions.
A detailed assessment involving full-body MRI scans of fifty individuals treated with pemvidutide showcased the drug’s capability to significantly maintain lean body mass. The body composition analysis indicated that 78.1% of the weight loss was due to fat reduction, whereas the loss of lean muscle mass constituted only 21.9%.
Additionally, improvements were noted in serum lipid levels and blood pressure among the pemvidutide recipients, with no clinically significant increases in heart rate or any notable imbalances in arrhythmias and other cardiac events being observed.
Vipin Garg, CEO of Altimmune, expressed satisfaction with the results, stating, “We are pleased with the data from MOMENTUM, which highlight the impressive lean mass preservation achieved with pemvidutide.” He further commented on the significance of maintaining muscle mass, which he deemed essential for healthy weight loss and optimal physical function. Garg also remarked that the outcomes with pemvidutide surpass those typically observed with conventional diet and exercise regimes, as well as other incretin-based weight loss treatments which reportedly lose about 40% of weight as lean mass.
Garg believes that the notable muscle preservation seen in the MOMENTUM study could distinctly position pemvidutide in the obesity treatment landscape.
Pemvidutide functions as a peptide-based agonist targeting both GLP-1 and glucagon receptors, which play roles in suppressing appetite and boosting energy expenditure, respectively. The dual mechanism of pemvidutide not only promotes weight loss but also mimics the physiological effects of exercise and diet on the body.
Looking forward, Altimmune has planned an end-of-Phase II meeting with the FDA, set for the third quarter of 2024. Approval of pemvidutide could position it as a significant treatment option for adults struggling with obesity. Moreover, the company is investigating pemvidutide’s potential in treating metabolic dysfunction-associated steatohepatitis in the ongoing Phase II IMPACT study, with a topline readout expected in the first quarter of 2025.
Read MoreIndia and China to introduce cheaper alternatives to popular obesity medications
As global demand for effective weight-loss medications surges, pharmaceutical companies in India and China are poised to disrupt the market by introducing cheaper versions of established obesity drugs, such as Wegovy. These firms are in the process of developing biosimilars, which are highly similar to original biologic drugs but are typically more affordable. This development is expected to make these crucial treatments accessible to a broader audience, especially in regions burdened with high rates of obesity.
Abhijit Zutshi, the Chief Commercial Officer at Biocon, headquartered in Bengaluru, India, highlighted the significant potential for Indian and Chinese companies to enhance global access to these medications. “There is huge potential for companies from India, China that can help create access to these drugs,” Zutshi explained, underlining the goal of providing affordable healthcare solutions to those in need.
The urgency is underscored by the alarming prevalence of obesity and overweight conditions globally, affecting approximately one billion individuals, many of whom reside in India and China. “Demand for anti-obesity drugs is very strong,” affirmed Lei Qian, Vice-President of Clinical Development at Innovent Biologics in Shanghai, illustrating the critical need for effective and accessible treatment options in these populous nations.
The drive to develop biosimilars is fueled by the success of a new class of weight-loss drugs that mimic the glucagon-like peptide 1 (GLP-1), a hormone that plays a crucial role in regulating blood sugar and appetite. The U.S. Food and Drug Administration (FDA) first approved GLP-1 drugs for weight loss in 2014, starting with Liraglutide (Saxenda). Subsequent developments led to more advanced formulations such as semaglutide (Wegovy) and tirzepatide (Zepbound), which offer significant weight loss benefits through weekly injections.
Despite their effectiveness, the cost of these treatments remains a barrier for many, with monthly expenses exceeding US$1,000. In response, companies like Biocon are innovating in drug synthesis and delivery to reduce these costs significantly. Zutshi remains optimistic about the potential for price reductions, suggesting that “it could be cut in half, or be one-tenth the current price.”
The patent landscape in China and India is rapidly evolving, with the patent for liraglutide already expired in China and semaglutide’s patent set to expire in 2026 in both countries. This change will allow more companies to produce and sell biosimilar versions, intensifying competition and potentially leading to further price reductions.
In addition to biosimilars, there are efforts underway to innovate beyond the existing drug formulas. For instance, Sun Pharmaceuticals in Mumbai is developing a new molecule, GL0034, which shows promise in early-stage trials to reduce body weight by up to 10% in just two months. Furthermore, a partnership between Innovent and Eli Lilly is focusing on Mazdutide, a dual-target drug that mimics both GLP-1 and glucagon, enhancing metabolism and fat burning. Lei anticipates that Mazdutide could receive approval from China’s drug regulator by the first half of 2025, marking a significant advancement in the treatment of obesity.
The introduction of these biosimilars and new drug formulations represents a transformative shift in the treatment of obesity, with the potential to make these life-changing medications accessible to millions more around the globe. As these developments unfold, the landscape of obesity treatment is set to change significantly, offering new hope and expanded options for those seeking to manage their weight effectively.
Read MoreBariatric surgery tops GLP-1 drugs and lifestyle changes in sustained weight loss efficacy
An extensive review of medical research from 2020 to 2024 has conclusively demonstrated that bariatric surgery, also referred to as metabolic or weight-loss surgery, yields the most substantial and longest-lasting weight loss results when compared to other interventions such as GLP-1 receptor agonists and lifestyle modifications. This significant finding was unveiled at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2024 Annual Scientific Meeting.
According to the research, lifestyle modifications, encompassing diet and physical exercise, typically lead to an average weight reduction of 7.4%. However, the study notes that this weight is often regained within approximately 4.1 years. In contrast, more intensive interventions like GLP-1 receptor agonists and surgical procedures have shown greater efficacy. The studies analysed involved thousands of participants across various clinical and randomised trials.
The research highlighted the effectiveness of GLP-1 semaglutide, which, with five months of weekly injections, resulted in a 10.6% reduction in body weight. A more pronounced effect was observed with tirzepatide, where nine months of treatment led to a 21.1% weight loss. Nevertheless, approximately half of this weight was regained within a year after cessation of treatment with either drug. If treatment was sustained, patients receiving tirzepatide stabilised at a 22.5% weight loss after 17-18 months, while those on semaglutide reached a plateau at 14.9% during the same timeframe.
More profound outcomes were observed with metabolic and bariatric surgeries such as gastric bypass and sleeve gastrectomy. These procedures showed a total weight loss of 31.9% and 29.5% respectively, one year post-operation. Remarkably, a weight loss of around 25% was maintained for up to a decade following the surgery.
“Metabolic and bariatric surgery remains the most effective and durable treatment for severe obesity,” explained Marina Kurian MD, a co-author of the study and bariatric surgeon at NYU Langone Health. She further emphasised the underutilisation of such surgeries, advocating for their consideration earlier in the treatment process rather than as a last resort.
In 2022, approximately 280,000 metabolic and bariatric procedures were conducted in the U.S., representing just about 1% of the eligible population based on Body Mass Index (BMI) criteria. This is in the context of a prevailing obesity rate of 42.4% among Americans, as reported by the U.S. Centers for Disease Control and Prevention (CDC). Obesity is known to compromise the immune system, enhance chronic inflammation, and escalate the risk of numerous health issues including cardiovascular diseases, stroke, type 2 diabetes, and certain types of cancer.
Dr. Ann Rogers, ASMBS President-elect and Professor of Surgery at Penn State College of Medicine, who was not involved in the study, highlighted the importance of surgical interventions in combating obesity. “While new drug treatments show great promise and could lead to more successful outcomes, particularly with better affordability and insurance coverage, we are still not fully utilising the most effective tool we have—metabolic and bariatric surgery, which is safer and more effective than ever,” she stated.
The study comprised a systematic review of various research studies that explored weight loss through lifestyle changes, GLP-1s (Semaglutide or tirzepatide), or metabolic and bariatric surgery. The review of GLP-1s was based on four randomised clinical trials conducted between 2021 and 2024. Lifestyle interventions were examined across eight studies, while surgical approaches were evaluated through a review of 35 studies, including two randomised trials, covering approximately 20,000 patients in total.
Read MoreExperts outline nutrition recommendations for patients treated with obesity medications
As individuals embark on treatment with anti-obesity medications, they frequently experience a diminished appetite which naturally leads to a reduction in food consumption. Given this reduced intake, ensuring a high quality of diet becomes crucial to meet the nutritional demands within the constraints of lower food consumption. To address these challenges, a team of medical experts has articulated a series of evidence-based nutritional guidelines designed to aid healthcare providers in managing patients on anti-obesity medications. These guidelines are detailed in a comprehensive review published in the journal “Obesity,” titled “Nutritional Considerations with Anti-Obesity Medications.”
Lisa M. Neff, the Executive Director of Global Medical Affairs for Obesity at Eli Lilly and Company, who is also the corresponding author of the review, emphasised the purpose of their findings: “Our evidence-based review aims to equip clinicians with knowledge and tools to help support optimal nutritional and medical outcomes for their patients treated with anti-obesity medications.”
The review advocates for the implementation of the “5A’s Model” (Ask, Assess, Advise, Agree, Assist) in clinical practice. This involves clinicians asking for permission to discuss weight management, conducting thorough assessments—including medical, psychosocial, dietary histories, and physical examinations—and identifying root causes of obesity along with any related complications.
After the assessment, healthcare providers should advise patients on treatment options and set realistic expectations. An agreement should be reached on health and lifestyle goals, with continuous assistance provided to overcome any barriers to effective weight management. Acknowledging the chronic nature of obesity, the review suggests regular follow-ups and referrals to dietitians as necessary.
The nutritional advice detailed in the review includes:
- Energy Intake: Tailor calorie intake based on individual factors such as age, sex, body weight, and activity level, with general recommendations of 1,200 to 1,500 kcal/day for women and 1,500 to 1,800 kcal/day for men during weight loss phases.
- Protein: Intake suggestions range from 60 to 75 g/day, with an upper limit of 1.5 g/kg body weight per day, emphasising sources like beans, nuts, seafood, and lean meats. Meal replacements can also be beneficial.
- Carbohydrates: Should constitute 45% to 65% of total energy, with a focus on whole grains, fruits, and vegetables, limiting added sugars to under 10%.
- Fats: Recommended to make up 20% to 35% of daily intake, with saturated fats kept below 10%, prioritising sources like avocados, fatty fish, and vegetable oils while avoiding high-fat and fried foods.
- Fibre: A daily intake of 21–25 g for women and 30–38 g for men is advised, using sources such as fruits, vegetables, and whole grains.
- Micronutrients: Emphasis on potassium, calcium, vitamin D, iron (for women of childbearing age), and vitamin B12 (in older adults), with a recommendation for increased fruit and vegetable consumption and possible supplementation.
- Fluids: A daily fluid intake of over 2 to 3 litres is encouraged, focusing on water and other low-calorie beverages, while limiting caffeine to avoid its diuretic effects.
Jessica Alvarez, Ph.D., RD, an associate professor of medicine at Emory University School of Medicine, not involved in the research, highlighted the broader implications of the study: “Simply focusing on weight loss is insufficient for optimal health,” she noted. “People with obesity are already at risk for some nutrient deficiencies. This is an important guide acknowledging the need for thorough nutritional assessment before and during treatment with anti-obesity medications.”
Alvarez also pointed out the necessity for detailed dietary guidance to prevent nutrient deficiencies and excessive muscle loss, calling for more rigorous clinical research to establish tailored dietary recommendations for this group.
The review’s methodology included a PubMed search using keywords related to diet, nutrition, and obesity, supplemented by expert consensus and observations from various related studies, including those on bariatric surgery and low-calorie diets. This narrative review underscores the importance of continued monitoring and adaptation of dietary guidelines to suit the evolving landscape of obesity treatment.
Read MoreOral semaglutide proven effective in managing type 2 diabetes and enhancing cardiovascular health
A meticulous study recently published in the Journal of Clinical Medicine has delved into the impact of oral semaglutide on patients with type 2 diabetes (T2D), highlighting its dual benefits on glycaemic control and cardiovascular wellness.
Semaglutide, distinguished as the inaugural oral anti-diabetic treatment specifically for T2D, functions as a glucagon-like peptide-1 receptor agonist (GLP-1RA). It has been proven to regulate glycaemic levels and reduce body weight (BW). Its safety and effectiveness have been corroborated through numerous clinical trials.
The extensive PIONEER programme assessed the efficacy of oral semaglutide across various stages of diabetes, involving treatment modalities that ranged from monotherapy to combination therapies with other oral glucose-lowering agents. Following the promising outcomes of this programme, the United States Food and Drug Administration (FDA) endorsed the drug in 2019, with subsequent approval by the European Medicines Agency (EMA) in 2020.
Guidelines in both America and Europe recommend oral semaglutide for T2D patients, especially those at high or very high risk of cardiovascular diseases (CVD), irrespective of their glycated haemoglobin (HbA1c) levels. This recommendation underscores the drug’s cardiovascular benefits.
However, the findings from the PIONEER study, though promising, call for further large-scale studies to conclusively determine the drug’s capability in reducing CVD risks. Additionally, the readiness of healthcare providers to incorporate this medication into everyday clinical practice warrants further evaluation.
The current retrospective study took place at two university-based diabetes centres in Italy, utilising data from an electronic chart system software designed for managing medical records in Italian diabetes outpatient clinics. This system recorded comprehensive patient data, including BW, HbA1c levels, waist circumference, serum creatinine, blood glucose levels, blood pressure, lipid profiles, aspartate aminotransferase (AST), estimated glomerular filtration rate (eGFR), among other laboratory results, as well as concurrent medications.
Patients received oral semaglutide during clinic visits, starting with a three mg dose, subsequently increased to seven mg, and in some cases, elevated to 14 mg to further enhance glycaemic control. These adjustments occurred over a monitoring period of up to six months.
The clinical improvements were notable in patients with recently diagnosed diabetes who showed significant enhancements in HbA1c levels and reductions in BW within six months of treatment initiation.
The study involved 192 Caucasian participants, predominantly around 67 years of age, with 44% being female and an average diabetes duration of nine years. Median fasting glucose and HbA1c levels stood at 146 mg/dL and 7.9%, respectively.
Prior to their oral semaglutide regimen, participants were treated with various medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2i), basal or fast-acting insulin, other GLP-1RAs, pioglitazone, metformin, DPP4 inhibitors, or sulfonylureas. During the six-month treatment phase with oral semaglutide, most patients were administered a seven mg dose, with only 2% receiving the 14 mg dose.
The study revealed no significant differences in HbA1c reduction between genders, but all participants experienced comparable weight loss. Significant improvements were also recorded in lipid profiles, waist circumference, blood pressure, and microalbuminuria levels after six months of treatment, underscoring oral semaglutide’s comprehensive benefits in metabolic health and CVD risk reduction.
In summary, oral semaglutide not only maintained optimal glycaemic control and facilitated weight reduction but also enhanced cardiovascular risk factors, including lipid profiles and blood pressure levels. The clinical relevance of oral semaglutide was evident even at a minimal dosage of seven mg, particularly among newly diagnosed patients, and the drug was well-tolerated even at the higher 14 mg dosage.
Read MoreBridging the gap: From obesity research to effective clinical practice
Recent advances in obesity research have considerably deepened our understanding of the condition’s underlying causes and the optimal strategies for its management. Despite these advances, a significant disparity exists in the application of this knowledge within clinical settings. This challenge has been meticulously outlined in the American Heart Association’s (AHA) scientific statement, “Implementation of Obesity Science Into Clinical Practice,” published in the Association’s leading journal, Circulation.
The statement asserts that obesity remains a critical public health issue, both in the United States and globally, affecting nearly all populations and imposing severe strains on healthcare systems. Obesity is a significant risk factor for heart disease, thus hindering progress in reducing heart disease rates. “Obesity is undeniably a critical public health concern in the U.S. and around the world, affecting nearly all populations and straining our health care systems. As a major risk factor for heart disease, obesity has significantly hindered progress in reducing heart disease rates. Despite advancements in understanding the complexities of obesity and newer treatment options, major gaps remain between obesity research and real-world implementation in clinical practice,” explains Deepika Laddu, Ph.D., FAHA, chair of the statement writing committee and senior research scientist at Arbor Research Collaborative for Health in Ann Arbor, Michigan.
The evidence strongly favours intensive lifestyle therapy, which is markedly more effective for weight loss than brief advice from healthcare professionals. However, the more common approach involves offering general educational information rather than directing patients toward specific classes, programmes, or tangible resources that facilitate lifestyle changes. One study highlighted that only 16% of healthcare professionals were knowledgeable about evidence-based lifestyle treatments for obesity, including diet and nutrition, physical activity, and intensive behavioural therapy referral. The barriers to effective weight management are further exacerbated by socioeconomic, racial, and ethnic disparities, with people of diverse backgrounds and those covered by Medicare or Medicaid less likely to be referred to or have weight management programs covered by their insurance.
Globally, the prevalence of obesity has been on the rise for around 30 years. Current estimates from the U.S. Centers for Disease Control and Prevention indicate that more than 40% of U.S. adults aged 20 and older are living with obesity. Research has elucidated the multifactorial causes of obesity, which include sociological and physiological determinants. Treatments have evolved to include more effective strategies for lifestyle modifications, medication therapy, and bariatric (weight-loss) surgery. Despite these advancements, each treatment approach faces its own set of challenges.
“Significant strides have been made in advancing the science to help us understand obesity, yet there remains a considerable gap between what we know and what happens in the doctor’s office,” Laddu observes. She emphasises the need for healthcare professionals and systems to better incorporate cutting-edge knowledge about obesity into practical applications so that more individuals can access appropriate support and treatment. This might include adopting new technologies and telemedicine, making referrals to community-based weight management programmes, providing social support, and enhancing the reach and access to treatments.
The statement discusses the FDA-approved Glucagon-like peptide-1 (GLP-1) agonists, such as high-dose semaglutide and tirzepatide, which are associated with an average weight loss of more than 10% at six months in clinical studies. Despite a large portion of the adult U.S. population meeting the BMI criteria for obesity and being eligible for these medications, a relatively small percentage currently use them. The historical lack of insurance coverage and high costs were significant barriers until recent policy changes by the Centers for Medicare and Medicaid Services allowed for the coverage of anti-obesity medications like semaglutide.
Weight loss surgery, or bariatric surgery, has seen improvements in safety, expertise, and understanding of its health benefits. A comprehensive review of studies on weight loss surgeries indicated that patients undergoing these procedures experienced lower risks of cardiovascular disease and reductions in other obesity-associated conditions such as Type 2 diabetes and high blood pressure. However, ensuring that the populations most in need have access to bariatric surgery remains a challenge due to cost, resource availability, and social support factors.
The statement further elaborates on the need for a comprehensive approach to obesity care, highlighting strategies to improve integration of obesity science into clinical practice and to develop solutions that manage obesity at the community level. The importance of education for healthcare professionals on the complex origins and clinical consequences of obesity is discussed, alongside the necessity for health policy changes to make obesity treatment more affordable, particularly for high-risk patients.
Specific approaches are highlighted in the statement to help bridge the gap between the science about obesity and clinical care, such as:
- To reach and successfully impact populations in need, healthcare professionals may consider how social determinants of health, including insurance type, household income, race and ethnicity, environment, health literacy, access to health-promoting resources, and social supports all influence the likelihood of successful patient treatment.
- Education for healthcare professionals explaining the complex origins and clinical consequences of obesity is discussed. Such training should emphasise information about diagnosis, prevention, and treatment of obesity. Despite the high prevalence of obesity around the world, there is a lack of education programmes centred on obesity for medical professionals.
- Further evaluation of health policy changes that healthcare systems and insurance plans can implement and scale in order to make obesity treatment affordable for patients, especially those at high risk for adverse outcomes such as cardiovascular disease.
- A framework for delivering obesity care into clinical practice settings is reviewed, as well as efforts by some professional societies for developing interventions that make obesity treatment more accessible.
“The statement emphasises the importance of a comprehensive approach across different levels of health care delivery and public policy, along with the adoption of feasible, evidence-based strategies in clinical settings,” said Laddu. “It also underscores the need for future research and policy changes to improve current patient care models and ensure equitable access to obesity-related care for people in underrepresented groups.”
The scientific statement also provides possible solutions for how to help people in their day-to-day lives, including interventions with digital technology and access through telemedicine. However, more research is needed in obesity science and treatment. Limited understanding of the cost-effectiveness of obesity prevention and the long-term health outcomes for established therapies has hindered the implementation of obesity science into clinical settings. Cross-collaborative obesity science research between stakeholders and health economists may serve as the bridge to developing and scaling cost-effective prevention programmes.
Further research into Food Is Medicine approaches in health care, such as medically tailored meals and produce prescriptions, to prevent and treat cardiovascular disease and other diet-related diseases are also being explored in several settings including the Association’s Health Care by FoodTM initiative.
This scientific statement was prepared by a dedicated volunteer group on behalf of various AHA councils, highlighting the critical need for increased awareness and informed healthcare decisions regarding obesity. While it outlines current knowledge and research needs, it refrains from making specific treatment recommendations, which are covered in the AHA’s official guidelines. This comprehensive approach underscores the necessity of closing the gap between advanced obesity research and its practical application in healthcare.
Read MoreAdults using semaglutide as first obesity medication achieve greater weight loss, study finds
A recent study has indicated that adults commencing semaglutide as their initial treatment for obesity experience more substantial weight reduction compared to those who had previously used other obesity medications. This research, published in the journal Diabetes, Obesity and Metabolism, was conducted by Andres J. Acosta, MD, PhD, and his team at the Mayo Clinic in Rochester, Minnesota. It marks the first investigation into how prior use of anti-obesity drugs influences weight loss outcomes with semaglutide.
The retrospective cohort study analysed data from 305 adults treated at a Mayo Clinic centre from 2021 to January 15, 2023. Participants, who had an average age of 49 and were predominantly female (73%), received once-weekly subcutaneous injections of semaglutide (Wegovy, Novo Nordisk). The research team monitored body weight changes from baseline at 3, 6, 9, and 12 months after initiating treatment. Additionally, blood pressure and laboratory values were assessed at baseline and after one year.
Of those studied, 76% had not previously used any obesity medication before starting semaglutide, while 24% had used another obesity drug. Among the latter group, 28% had been treated with the GLP-1 receptor agonist liraglutide (Saxenda, Novo Nordisk), and 72% had used a non-GLP-1 obesity medication.
The findings revealed that those who were new to obesity medications and started with semaglutide saw a 14.3% reduction in body weight by 12 months, compared to a 10.6% decrease in those who had used other obesity treatments prior (P = .01). Despite similar proportions of both groups achieving at least 5% and 10% body weight loss, those new to obesity medication were significantly more likely to lose at least 15% (48% vs. 21%; P = .02) and at least 20% (27% vs. 4%; P < .01) of their body weight.
The analysis also showed a distinct pattern in weight loss during the first six months, where those without prior obesity medication use consistently lost more weight than those who had previously used liraglutide or other non-GLP-1 obesity drugs. By nine and twelve months, while weight loss among previous liraglutide users remained lower, those who had used other non-GLP-1 medications achieved similar weight loss to the semaglutide-naive group.
An interesting finding was that adults not previously on obesity medications exhibited a significant reduction in HbA1c levels at 12 months compared to their counterparts who had used such medications before (P < .001), although no other significant differences in metabolic outcomes were noted.
The study highlights a potential issue where prior usage of specific obesity treatments like liraglutide might lessen responsiveness to new medications such as semaglutide. The researchers suggested that these findings underscore the necessity for precision medicine in obesity management, advocating for treatment plans tailored to individual genetic backgrounds, environmental factors, and prior medication history to optimise effectiveness, reduce unnecessary drug exposure, and consider financial impacts on patients.
This study opens the door for further prospective research to explore and confirm the differential impacts of switching obesity medications and to enhance the understanding of optimal treatment strategies in obesity management.
Read More